Skip to content
Jupiter Life Line Hospital logo

Jupiter Life Line Hospital

Jupiter Life Line Hospitals Ltd

JLHL NSE
₹279.55 +16.65 (+6.33%)
P/E
48.87
View as Markdown
MCP
Close 4 Nov 2026 ₹279.55 −31.17 −10.0% 1Y
Start ₹310.72

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
14.80%
Debt to Equity
0.38
EPS (TTM)
₹5.72
Book Value
₹49.73
Market Cap
—
P/E (TTM)
48.87
P/B
5.62
ROE
13.10%
Dividend Yield
0.38%
EBITDA
₹386 Cr
52W High
₹340.00
52W Low
₹233.40
Day Range
₹264.20 – ₹284.90
Volume
1,39,755

Peer Comparison

Healthcare › Healthcare Services › Hospitals › Hospital

Jupiter Life Line Hospital peer comparison
Apollo Hospitals
₹8,599.5059.18₹1,22,850 Cr13.040.24%21.20%17.40%₹26,430 Cr₹2,171 Cr
Max Healthcare Institute
₹927.1561.89₹89,301 Cr7.960.22%14.70%14.70%₹8,712 Cr₹1,457 Cr
Manipal Health Enterprises
₹667.2088.96₹86,479 Cr5.340.00%6.64%8.30%₹11,400 Cr₹906 Cr
Aster DM Healthcare
₹719.55117.00₹59,927 Cr14.910.44%11.30%11.60%₹4,876 Cr₹363 Cr
Fortis Healthcare
₹790.6556.96₹59,706 Cr6.030.13%11.20%13.40%₹9,506 Cr₹1,070 Cr
Narayana Hrudayalaya
₹1,931.5048.36₹39,090 Cr7.890.24%20.50%15.50%₹9,072 Cr₹816 Cr
Global Health
₹1,402.0067.76₹37,618 Cr9.520.04%15.20%17.40%₹4,683 Cr₹552 Cr
Jupiter Life Line Hospital (this company)
₹279.5548.87₹8,792 Cr5.620.38%13.10%14.80%₹1,558 Cr₹187 Cr
Median 8 companies₹858.9060.54₹59,817 Cr7.930.23%13.90%14.75%₹8,892 Cr₹861 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

43 Weak

Data confidence 100/100

Category scores

Quality
45
Average
Returns, margins, earnings quality 22% weight
Valuation
36
Poor
Cheap vs sector & own history 24% weight
Growth
46
Average
Sales & profit trajectory 9% weight
Financial Health
30
Poor
Solvency, leverage, coverage 9% weight
Momentum
41
Weak
Trend strength, vol-adjusted 12% weight
Ownership
61
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 143% CAGR over last 5 years

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4312
OscillatorsNeutral333
Moving AveragesStrong Bullish109

Key readings

RSI (14)
66.66
Neutral
MACD (12,26,9)
−0.09
Bullish
SMA (50)
268.77
Bullish
SMA (200)
270.50
Bullish

As of

Analyst Rating

Based on 5 analysts
BUY80%

4 of 5 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
4
80%
HOLD
1
20%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+25.28%
3Y+18.87%
1Y+15.21%
TTM+14.73%

Net profit

Net profit growth by window
5YTurned to profit
3Y+38.51%
1Y0.00%
TTM−3.11%

Operating cash flow

Operating cash flow growth by window
5Y+16.85%
3Y+15.05%
1Y+0.37%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+9.08 pp
3Y+0.36 pp
1Y−0.40 pp
TTM−0.95 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹463 Cr
Mar 2021₹486 Cr
Mar 2022₹733 Cr
Mar 2023₹893 Cr
Mar 2024₹1,073 Cr
Mar 2025₹1,302 Cr
Mar 2026₹1,500 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹30.00 Cr
Mar 2021−₹2.00 Cr
Mar 2022₹51.00 Cr
Mar 2023₹73.00 Cr
Mar 2024₹177 Cr
Mar 2025₹194 Cr
Mar 2026₹194 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹110 Cr −6.3% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 31 Jul 2026
AI opinion · based on fundamentals
Risk high

Jupiter Life Line Hospitals Ltd is a western-India focused hospital chain with a market cap of ₹10,792 crore, trading at a PE of 56.1x. FY26 consolidated revenue grew 15.2% YoY to ₹1,500 crore with EBITDA of ₹343 crore (22.9% margin), while full-year PAT was essentially flat at ₹194 crore. The company is in an aggressive expansion phase, targeting 2,500 beds by FY28-29 from its current base.

Bull Case 8
  • Strong 5-year profit CAGR of 143%, reflecting a significant earnings ramp-up from a low base as the hospital network matured
  • FY26 revenue grew 15.2% YoY to ₹1,500 crore, demonstrating consistent top-line momentum even as new capacity ramps up
  • ARPOB (Average Revenue Per Occupied Bed) grew 11.7% YoY to ₹67,700 in Q4 FY26, indicating improving case mix and pricing power
  • Clear bed expansion visibility from ~1,060 operational beds to 2,500 beds by FY28-29 across MMR, Pune, and Indore — a potential doubling of capacity
  • Dombivli greenfield hospital commissioned ahead of schedule and on budget, demonstrating execution capability on capital projects
  • Company remains cash-positive and is funding growth through internal accruals with capped debt, reducing dilution risk
  • 3-year compounded sales CAGR of 19% and 3-year profit CAGR of 37% show sustained growth trajectory beyond one-off gains
  • Q4 FY26 quarterly revenue hit ₹388 crore (up 15.1% YoY) with Q4 PAT rising 12.7% to ₹50.6 crore, showing sequential improvement
Bear Case 7
  • Stock trades at 7.06x book value, a steep premium that prices in significant future execution on expansion plans
  • Full-year FY26 PAT was nearly flat at ₹194 crore vs ₹194 crore in FY25 (TTM profit growth of -1%), showing earnings stagnation despite revenue growth
  • EBITDA margin dipped to 22.9% in FY26 from higher levels, pressured by new hospital ramp-up costs and rising employee expenses (up 11% YoY in Q3)
  • Bed occupancy at 61.2% for the three established hospitals suggests room to fill before new capacity additions become earnings-accretive
  • Expansion concentrated in western India (MMR, Pune, Indore) creates geographic concentration risk with limited diversification
  • Higher depreciation and finance costs from expansion capex compressed Q1 FY26 PAT by 1.6% YoY even as EBITDA grew 19.6%, a trend likely to persist
  • Dividend yield of just 0.3% offers negligible income return, making the stock entirely dependent on capital appreciation

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

94d ago

TL;DR: Jupiter Life Line Hospitals is growing revenue at a healthy 16.4% clip and actively expanding via acquisitions, but profitability is under pressure with net profit declining 14.4% due to rising operational and finance costs. The top-line trajectory is encouraging, though margin compression remains a near-term risk to monitor. If cost pressures ease or get absorbed through scale, earnings growth could re-accelerate in coming quarters.

Headwinds 1
  • Net profit falls 14% in Q1 Aug 1

    Net profit declined 14.4% to ₹375.12 million in Q1FY27 despite revenue growth, driven by rising operational and finance costs.

Positives 3
  • Revenue surges 16.4% in Q1 Aug 1

    Q1FY27 revenue grew 16.4% to ₹4,109.83 million, indicating strong top-line momentum and demand for hospital services.

  • Sulcus acquisition completed Aug 1

    Completed acquisition of Sulcus Private Limited for ₹3.78 crore, expanding the company's footprint.

  • New CFO appointed Aug 1

    Harshad Purani appointed as CFO, strengthening the leadership team.

Neutral 1
  • 24th AGM held, resolutions approved Jul 17

    Jupiter Life Line Hospitals held its 24th AGM on July 17, 2026, approving financial statements and key resolutions.

Quarterly Results

₹ Cr
JLHL quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
243
263
273
290
287
335
333
337
353
394
365
388
411
456
Expenses
190
202
211
228
223
257
256
257
275
301
282
299
332
350
Operating Profit
53
61
62
63
65
78
76
80
78
92
83
89
79
107
OPM %
22%
23%
23%
22%
23%
23%
23%
24%
22%
23%
23%
23%
19%
23%
Other Income
5.01
3.97
8
8.95
8.37
7
8.3
7
13
11
3
9.15
11
11
Interest
12
12
1
1
1
1
3
6
8
8
8
9
13
14
Depreciation
11
11
11
10
11
14
14
18
21
21
22
23
26
28
PBT
34
41
58
62
60
70
67
62.1
62
74
57
66.05
51
75
Tax %
−60%
19%
25%
27%
26%
26%
22%
28%
29%
23%
25%
26%
26%
25%
Net Profit
54
34
44
45
45
52
52.51
45
44
57
42
48.76
38
56
EPS (₹)
1.91
1.03
1.33
1.37
1.36
1.58
1.59
1.38
1.34
1.75
1.3
1.53
1.14
—

Sep 2026: from the results filed on 23 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
JLHL profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
463
486
733
893
1,073
1,302
1,500
1,558
Expenses
379
419
580
691
831
999
1,156
1,214
Operating Profit
84
67
153
201
242
303
343
344
OPM %
18%
14%
21%
23%
23%
23%
23%
22%
Other Income
0
4
4
8
22
25
42.37
35
Interest
26
39
44
42
26
11
33
37
Depreciation
26
31
36
39
42
57
88
93
PBT
33
2
77
129
195
261
265
249
Tax %
10%
248%
34%
43%
10%
26%
25%
—
Net Profit
30
−2
51
73
177
194
199
188
EPS (₹)
1.17
−0.09
2.01
2.58
5.39
5.89
5.92
5.72
Div. Payout %
0%
0%
0%
0%
4%
3%
3%
—

Balance Sheet

₹ Cr
JLHL balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
51
51
51
57
66
66
66
Reserves
186
188
243
309
1,103
1,291
1,479
Borrowings
272
426
495
469
0
393
584
Other Liabilities
94
124
120
151
112
168
235
Total Liabilities
603
789
909
986
1,281
1,917
2,363
Fixed Assets
435
630
684
720
718
978
1,384
CWIP
10
26
27
29
74
185
129
Investments
2
7
3
2
17
507
486
Other Assets
156
126
195
235
473
247
364
Total Assets
603
789
909
986
1,281
1,917
2,363

Cash Flow

₹ Cr
JLHL cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
74
123
137
176
115
267
268
Investing
−43
−295
−84
−94
−246
−497
−442
Financing
−32
184
32
−51
128
297
136
Net Cash Flow
−1
12
85
31
−3
66
−38
Free Cash Flow
46
−118
46
100
29
−60
−234
CFO/EBITDA
106
198
95
97
68
109
97

Ratios

JLHL financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
35
16
14
19
19
12
18
Inventory Days
64
48
39
44
41
38
49
Days Payable
268
217
157
164
120
99
121
Cash Conversion Cycle
−169
−152
−104
−101
−59
−49
−54
Working Capital Days
17
−7
−24
−24
−5
−19
−21
ROCE %
—
7%
17%
21%
22%
18%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jupiter Life Line Hospital insights

64 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 40.91%
  • Public 22.68%
  • DIIs 19.13%
  • FIIs 9.13%
  • Others 8.15%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Jupiter Life Line Hospital

What does Jupiter Life Line Hospitals Ltd do?
Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.
Where is Jupiter Life Line Hospitals Ltd (JLHL) listed?
Jupiter Life Line Hospitals Ltd trades as JLHL on the NSE and under code 543980 on the BSE.
Which sector does Jupiter Life Line Hospitals Ltd belong to?
Jupiter Life Line Hospitals Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the PE ratio of Jupiter Life Line Hospitals Ltd?
Jupiter Life Line Hospitals Ltd trades at a PE ratio of 48.87 as of 4 Nov 2026, on earnings per share of ₹5.72, against a book value of ₹49.73 per share.
What is the 52-week high and low of Jupiter Life Line Hospitals Ltd?
Over the last 52 weeks Jupiter Life Line Hospitals Ltd has traded between ₹233.4 and ₹340 as of 4 Nov 2026.
Does Jupiter Life Line Hospitals Ltd pay dividends?
Jupiter Life Line Hospitals Ltd has a dividend yield of 0.38%.
What is the Return on Equity (ROE) of Jupiter Life Line Hospitals Ltd?
Jupiter Life Line Hospitals Ltd reported a return on equity of 13.10%. Its debt-to-equity ratio is 0.38.

Company Information

Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.

Website jupiterhospital.com
Listed 18 Sep 2023
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JLHL.md for Jupiter Life Line Hospitals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month